目的：探讨黑色素瘤相关抗原-C1（melanoma-associated antigen-C1, MAGE-C1）在乳腺癌组织中的表达及其与患者临 床病理特征和预后的关系。方法：选取2008年1月至2008年12月河北医科大学第四医院乳腺中心行手术切除的乳腺癌、正常 乳腺组织及良性乳腺病变组织各60例， 用RT-PCR和免疫组织化学染色法分别检测3种组织中MAGE-C1 mRNA和蛋白的表达 水平，分析MAGE-C1表达与乳腺癌患者临床病理特征及预后的关系。用DNA甲基化酶抑制剂5-氮杂-2'-脱氧胞苷（5-Aza-CdR） 和组蛋白去乙酰化酶抑制剂曲古抑菌素A（TSA）干预乳腺癌MDA-MB-231和MCF-7细胞，RT-PCR法检测药物干预前后细胞中 MAGE-C1 mRNA表达的变化。结果：乳腺癌组织中MAGE-C1 mRNA及蛋白表达阳性率分别为43.3%（26/60）和38.3%（23/60）， 乳腺正常组织及良性病变组织中均未发现MAGE-C1 mRNA 和蛋白的表达。MAGE-C1表达与乳腺癌患者的组织学分级相关 （χ2 =6.233，P<0.05）。MAGE-C1 表达阳性的患者 ，其无复发生存率低于 MAGE-C1 表达阴性的患者（χ2=4.213，P<0.05）。 MAGE-C1表达（HR=3.980，P<0.05）和临床分期（HR=3.637，P<0.05）是影响乳腺癌患者预后的独立危险因素。单独或联合应用 5-Aza-CdR和TSA对乳腺癌细胞中MAGE-C1的表达均无影响（P>0.05）。结论：MAGE-C1是肿瘤特异性抗原，其表达与乳腺癌 患者的不良预后密切相关。

Objective: To investigate the expression of MAGE-C1 (melanoma-associated antigen-C1) in breast cancer tissues and its correlation with clinicopathological features and prognosis of breast cancer patients. Methods: Breast cancer tissues, normal breast tissues and benign breast lesion tissues (60 samples for each) were collected from the Fourth Hospital of Hebei Medical University during January2008andDecember2008.ThemRNAand protein expressions of MAGE-C1 in three types of breast tissues were detected by RT-PCR and immunohistochemistry, and their correlation with clinicopathological parameters and prognosis of breast cancer patients were also analyzed. DNAmethylaseinhibitor5-aza-2'-deoxycytidine(5-Aza-CdR)and histone deacetylase inhibitor trichostatin A (TSA) were used to treat breast cancer MDA-MB-231 and MCF-7 cells, and RT-PCR was used to determine the changes in mRNA expression of MAGE-C1 after drug treatment. Results: The positive expression rate of MAGE-C1 mRNA and protein in breast cancer tissues were 43.3% (26/60) and 38.3% (23/60), respectively; and the mRNA and protein expressions of MAGE-C1 were all negative in normal breast tissues and benign breast lesion tissues. MAGE-C1 expression was positively associated with high tumor grade (χ2=6.233, P<0.05). Recurrence-free survival (RFS) of patients with negative MAGE-C1 expression was significantly longer than those patients with positive MAGE-C1 expression (χ2=4.213, P<0.05). MAGE-C1 expression (HR=3.980, P<0.05) and clinical stage (HR=3.637, P<0.05) could be used as independent prognostic factors for breast cancer patients. 5-Aza-CdR and/or TSA treatment had no significant influence on MAGE-C1 gene expression (P>0.05). Conclusion: MAGE-C1 is a tumor-specific antigen and its expression is associated with poor prognosis of breast cancer patients.

河北省杰出青年基金资助项目（No. H2019206697）